SCI (4119) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 旭富

SCI (4119) reported revenue of NT$131 million for Oct 2026, +30.4% year on year and -19.8% from the previous month. Revenue for Jan–Oct 2026 was NT$1.28 billion (+17.8% year on year).

Year-on-year revenue growth: 5 months in a row. →

In Oct 2026, it ranked No. 63 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$168.4 million24/10Nov 2024 NT$155.5 millionDec 2024 NT$78 millionJan 2025 NT$106.9 millionFeb 2025 NT$84.7 million25/02Mar 2025 NT$168.8 millionApr 2025 NT$165.8 millionMay 2025 NT$115.2 millionJun 2025 NT$90.5 million25/06Jul 2025 NT$81.8 millionAug 2025 NT$51.8 millionSep 2025 NT$122.8 millionOct 2025 NT$100.5 million25/10Nov 2025 NT$103.4 millionDec 2025 NT$151.6 millionJan 2026 NT$129.7 millionFeb 2026 NT$118.5 million26/02Mar 2026 NT$127.6 millionApr 2026 NT$88.7 millionMay 2026 NT$60.9 millionJun 2026 NT$123.2 million26/06Jul 2026 NT$190.8 millionAug 2026 NT$149 millionSep 2026 NT$163.4 millionOct 2026 NT$131 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$131 million+30.4%-19.8%
Sep 2026NT$163.4 million+33.1%+9.7%
Aug 2026NT$149 million+187.5%-21.9%
Jul 2026NT$190.8 million+133.2%+54.8%
Jun 2026NT$123.2 million+36.1%+102.3%
May 2026NT$60.9 million-47.1%-31.3%
Apr 2026NT$88.7 million-46.5%-30.5%
Mar 2026NT$127.6 million-24.4%+7.7%
Feb 2026NT$118.5 million+39.9%-8.6%
Jan 2026NT$129.7 million+21.4%-14.5%
Dec 2025NT$151.6 million+94.5%+46.7%
Nov 2025NT$103.4 million-33.5%+2.9%
Oct 2025NT$100.5 million-40.3%-18.2%
Sep 2025NT$122.8 million-7.2%+137.0%
Aug 2025NT$51.8 million-65.6%-36.7%
Jul 2025NT$81.8 million-40.1%-9.6%
Jun 2025NT$90.5 million-21.5%-21.4%
May 2025NT$115.2 million-0.1%-30.5%
Apr 2025NT$165.8 million+2.2%-1.8%
Mar 2025NT$168.8 million+18.0%+99.3%
Feb 2025NT$84.7 million+14.4%-20.7%
Jan 2025NT$106.9 million+15.0%+37.1%
Dec 2024NT$78 million-12.2%-49.9%
Nov 2024NT$155.5 million+43.2%-7.6%
Oct 2024NT$168.4 million+78.9%+27.2%

Jan–Oct 2026 cumulative: NT$1.28 billion (+17.8% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: SCI vs PEC / SCI vs Lotus Pharm / SCI vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16